Nanovaccine targeting in colorectal cancer: a multi-dataset analysis of CEA expression, cytokine profiles, and co-expressed genes
CEACAM5 defines a distinct immune-silent tumor phenotype and co-localizes with other vaccine-relevant genes such as EPCAM. This study provides a comprehensive immunogenomic rationale for CEACAM5-directed nanovaccine development and proposes EPCAM and ATP10B as co-targets based on tumor-specific and developmental expression profiles.
Authors
- Cristina Mitrea
- Lucian Constantin MOCAN (ORCID: https://orcid.org/0000-0002-7444-7978)
- Razvan-Septimiu Zdrehus
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- University of Michigan (US)
Publication Details
- Journal
- Medicine and Pharmacy Reports
- Published
- 2025-07-26
- DOI
- https://doi.org/10.15386/mpr-2917
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36